medigraphic.com
ISSN 0188-9796 (Print)

2000, Number 4

<< Back Next >>

Rev Endocrinol Nutr 2000; 8 (4)

Advances and therapeutic perspectives in more important hormone dependent tumors and benign prostatic hyperplasia

Vadillo BM, González BD, Caracas PN, Zelaya GLÁ, Vega SR, Gómez RAM

Language: Spanish
References: 20
Page: 113-118
PDF size: 164.83 Kb.


ABSTRACT

The incidence and identification of hormone dependent cancer is still in the rise. Recently, the characterization of cytoplasmic and membrane receptors have become necessary to administrate a highly specific therapy free of side effects. Their characterization can be obtained by a series of methods of which radioligand binding assays are the most important of them all. We have identified the expression of these receptors in tissues from pancreas, the gastrointestinal system, prostate, thyroid, breast, colon and benign prostatic hyperplasia specifically for the epidermal growth factor and the insulin-like growth factor 1. In the future, the use of hormonal analogues of bombesin/gastrin releasing peptide, growth hormone releasing hormone and luteinizing hormone releasing hormone will increase the quality of life and will allow a highly promising and efficacious therapy for patients with these neoplasms.


REFERENCES

  1. Vadillo BM. Actualidades y perspectivas endocrinas en cáncer. Rev Mex End y Nut 1996; 4(1): 1-5.

  2. Vadillo BM, Caracas PN, Rodríguez RF, Cuevas MOJ, Normandia AM, González BD. Sitios de unión al receptor para el factor de crecimiento epidérmico (EGF-R) en neoplasias colorrectales humanas por medio de estudios de competencia con radioligandos. (Resultados preliminares). XXXVIII Reunión Anual SMNE, Morelia, Mich, Mex, Suplem 1998, resumen 88.

  3. Ishizuka J, Martínez J, Townsend CM, Thompson JC. The effect of gastrin on growth of human stomach cancer cells. Ann Surg 1992; 215(5): 528-535.

  4. Watson S, Crosbee DM, Morris DL, Robertson JFR, Makovec F, Rovati LC, Hardeastle JD. Therapeutic effect of the gastrin receptor antagonist, CR 2093 on gastrointestinal tumour cell growth. Br J Cancer 1992; 65: 879-883.

  5. Watson S, Durrant L, Elston P, Morris D. Inhibitory effects of the gastrin receptor antagonist (L-365, 260) on gastrointestinal tumour cells. Cancer 1991; 68(6): 1255-1260.

  6. Preston SR, WoodHouse LF, Jones-Blackett S, Wyatt JI, Primrose JN. High affinity binding sites for gastrin releasing peptide on human gastric cancer and Menetrier’s mucosa. Br J Cancer 1995; 71(5): 1087-1089.

  7. Kore M. Growth factors and pancreatic cancer Int J Pancreatol 1991; 9: 87-91.

  8. González BD, Ibarra OMA, García CF, Gutiérrez SC, Camaru-Schally AM, Schally AV. Influence of D-Trp-6-LH-RH on the survival time in patients with advanced pancreatic cancer. Biomed Pharmacother 1989; 43: 313-317.

  9. Vadillo BM, Halmos G, Szepeshazi K, Rodríguez ME, Schally AV. Down regulation of receptors for EGF in nitrosamine-induced pancreatic cancer in Hamsters by a single administration of bombesin antagonist RC-3095. Abstract Book Vol II: June 14-15. Abst Nº P3-711. 932, 10th International Congress of Endocrinology, San Francisco, CA, USA 1996.

  10. Parker SL, Tong T, Boden S, Wingo PA. Cancer Statistics, 1996. CA Cancer J Clin 1996; 65: 5-27.

  11. Minna JD, Pass H, Gladstein. Cancer of the lung, In: V.T. De Vita, S. Hellman and S.A Rosenberg (eds), Cancer, Principles and Practice of Oncology J.B Lippincott Company, Philadelphia 1989: 591-705.

  12. Pfeiffer P, Clausen PP, Andersen K, Rose C. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: An inmunohistochemical study on cryosections. Br J Cancer 1996; 74(1): 86-91.

  13. Johnson BE. Biologic and molecular prognostic factors-impact on treatment of patients with non-small cell lung cancer. Chest 1995; 107 (6 Suppl): 287S-290S.

  14. Pinsky J, Schally AV, Jungwirth A, Groot K, Halmos G, Armantis P, Zarandi M, Vadillo BM. Inhibition of growth of human small cell and non-small cell lung carcinomas by antagonists of growth hormone releasing hormone (GH-RH). Int J Oncol 1996; 9: 1099-1105.

  15. Byrne KJ, Halmos G, Pinski J, Groot K, Szepeshazi K, Schally AV, Carney DN. Somatostatin receptor expression in lung cancer. Eur J Cancer 1994; 30A(11): 1682-1687.

  16. González BD, Vadillo BM, Gómez OF, Fuentes GM, Cárdenas CI, Graef SA, Camaru-Schally AM, Schally AV. Responses to the antagonistic analog of LH-RH, SB-75, Cetrorelix in patients with benign prostatic hyperplasia and prostatic cancer. Prostate 1994; 24: 84-92.

  17. Caracas PN, Vadillo BM, González BD. Expresión de los receptores para el factor de crecimiento epidérmico (EGF-R) en muestras de hiperplasia prostática benigna en humanos mediante el empleo de estudios de competencia con radioligandos, tesis para obtener el título de Endocrinólogo 1999: 1-37.

  18. Szepeshazi K, Halmos G, Schally AV, Arencibia JM, Groot K, Vadillo BM, Rodríguez ME. Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs. J Cancer Res Clin Oncol 1999; 125: 444-452.

  19. Vadillo BM, Caracas PN, Pizarro CMA, German HA, González BD. Expresión del receptor para el factor de crecimiento epidérmico (EGF-R) como marcador de pronóstico y perspectivas terapéuticas en pacientes con cáncer de tiroides y sus metástasis (Resultados Preliminares) Rev Argentina de Endocrinol y Metab 2000, Vol 37 suplemento, resumen Nº 6 p 22.

  20. Sainsbury JRC, Sherbet GV, Farndon JR, Harris AL. Epidermal growth factor receptors and oestrogen receptors in human breast cancer. Lancet 1985; 1(8425): 364-366.




2020     |     www.medigraphic.com